Serum galectin-9 as a noninvasive biomarker for the detection of endometriosis and pelvic pain or infertility-related gynecologic disorders

Brubel R, Réka Brubel, Reka Brubel, Bokor A, Attila Bokor, Akos Pohl, Ákos Pohl, Pohl A, Schilli GK, Gabriella Krisztina Schilli, Gabriella Schilli, Laszlo Szereday, László Szereday, Bacher-Szamuel R, Reka Bacher-Szamuel, János Rigó, J Rigó, Janos Rigo, Rigo J Jr, Beata Polgar, Polgar B, Beáta Polgár
Fertility and sterility · 2017 · vol. 108(6) , pp. 1016–1025.e2 · doi:10.1016/j.fertnstert.2017.09.008 · PMID:29202955 · W2775080747
Other OA: closed CC0 ⤵ 22 in-corpus citations
🔓 Open OA copy View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-08 ⓘ

This study investigated serum galectin-9 as a potential noninvasive biomarker for detecting endometriosis and gynecologic disorders associated with pelvic pain or infertility.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

OBJECTIVE: To investigate the usefulness of soluble galectin-9 (Gal-9) in the noninvasive laboratory diagnosis of endometriosis and various gynecologic disorders. DESIGN: Prospective case-control study. SETTING: University medical centers. PATIENT(S): A total of 135 women of reproductive age were involved in the study, 77 endometriosis patients, 28 gynecologic controls, and 30 healthy women. INTERVENTION(S): Diagnostic laparoscopy and collection of tissue biopsies, peritoneal cells, and native peripheral blood from different case groups of gynecology patients and healthy women. MAIN OUTCOME MEASURE(S): The expression of mRNA and serum concentration of Gal-9. RESULT(S): Semiquantitative reverse transcription-polymerase chain reaction analysis and serum soluble Gal-9 ELISA were performed on three different cohorts of patients: those with endometriosis, those with benign gynecologic disorders, and healthy controls. Differences in the Gal-9 concentrations between the investigated groups and the stability of Gal-9 in the serum and diagnostic characteristics of Gal-9 ELISA were determined by statistical evaluation and receiver operating characteristic (ROC) curve analysis. Significantly elevated Gal-9 levels were found in both minimal-mild (I-II) and moderate-severe (III-IV) stages of endometriosis in comparison with healthy controls. At a cutoff of 132 pg/mL, ROC analysis revealed an excellent diagnostic value of Gal-9 ELISA in endometriosis (area under the curve = 0.973) with a sensitivity of 94% and specificity of 93.75%, indicating better diagnostic potential than that of other endometriosis biomarkers. Furthermore, various pelvic pain or infertility-associated benign gynecologic conditions were also associated with increased serum Gal-9 levels. CONCLUSION(S): Our results suggest that Gal-9 could be a promising noninvasive biomarker of endometriosis and a predictor of various infertility or pelvic pain-related gynecologic disorders.

My notes (saved in your browser only)

Condition tags

endometriosischronic_pelvic_paininfertility

MeSH descriptors

Endometriosis Galectins Infertility, Female Pelvic Pain Adult Adult Area Under Curve Area Under Curve Biomarkers Biomarkers Biomarkers Case-Control Studies Case-Control Studies Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Enzyme-Linked Immunosorbent Assay Enzyme-Linked Immunosorbent Assay

Funding

funders
[{'doi': '10.13039/501100011019', 'name': 'Nemzeti Kutatási Fejlesztési és Innovációs Hivatal', 'awards': ['K119529']}]

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (100)

Cited by (24)

Source provenance

crossref
last seen: 2026-05-25T01:00:27.284319+00:00
europepmc
last seen: 2026-10-13T06:10:10.580696+00:00
openalex
last seen: 2026-06-04T00:00:01.174412+00:00
pubmed
last seen: 2026-10-08T21:20:57.725456+00:00
unpaywall
last seen: 2026-09-17T06:32:46.214484+00:00
License: CC0 · commercial use OK